Raatikainen M J Pekka, Arnar David O, Zeppenfeld Katja, Merino Jose Luis, Levya Francisco, Hindriks Gerhardt, Kuck Karl-Heinz
Department of Medicine Division of Cardiology, Central Finland Health Care District, Jyväskylä and University of Eastern Finland, Building 1 D/9, FI-40620 Jyväskylä, Finland
The Heart Centre, Department of Medicine, Landspitali - The National University Hospital, Reykjavik, Iceland.
Europace. 2015 Jan;17 Suppl 1:i1-75. doi: 10.1093/europace/euu300.
There has been large variations in the use of invasive electrophysiological therapies in the member countries of the European Society of Cardiology (ESC). The aim of this analysis was to provide comprehensive information on cardiac implantable electronic device (CIED) and catheter ablation therapy trends in the ESC countries over the last five years.
The European Heart Rhythm Association (EHRA) has collected data on CIED and catheter ablation therapy since 2008. Last year 49 of the 56 ESC member countries provided data for the EHRA White Book. This analysis is based on the current and previous editions of the EHRA White Book. Data on procedure rates together with information on economic aspects, local reimbursement systems and training activities are presented for each ESC country and the five geographical ESC regions.
In 2013, the electrophysiological procedure rates per million population were highest in Western Europe followed by the Southern and Northern European countries. The CIED implantation and catheter ablation rate was lowest in the Eastern European and in the non-European ESC countries, respectively. However, in some Eastern European countries with relative low gross domestic product procedure rates exceeded those of some wealthier Western countries, suggesting that economic resources are not the only driver for utilization of arrhythmia therapies.
These statistics indicate that despite significant improvements, there still is considerable heterogeneity in the availability of arrhythmia therapies across the ESC area. Hopefully, these data will help identify areas for improvement and guide future activities in cardiac arrhythmia management.
欧洲心脏病学会(ESC)成员国在侵入性电生理治疗的使用上存在很大差异。本分析的目的是提供过去五年ESC国家心脏植入式电子设备(CIED)和导管消融治疗趋势的全面信息。
自2008年以来,欧洲心律协会(EHRA)一直在收集CIED和导管消融治疗的数据。去年,56个ESC成员国中有49个为EHRA白皮书提供了数据。本分析基于EHRA白皮书的当前版本和上一版本。列出了每个ESC国家和五个ESC地理区域的手术率数据以及经济方面、当地报销系统和培训活动的信息。
2013年,每百万人口的电生理手术率在西欧最高,其次是南欧和北欧国家。CIED植入率和导管消融率分别在东欧和非欧洲ESC国家最低。然而,在一些国内生产总值相对较低的东欧国家,手术率超过了一些较富裕的西方国家,这表明经济资源不是心律失常治疗利用的唯一驱动因素。
这些统计数据表明,尽管有显著改善,但整个ESC地区心律失常治疗的可及性仍存在相当大的异质性。希望这些数据将有助于确定改进领域,并指导未来心律失常管理活动。